The expression of the following oncogene is associated with a high incidence of Medullary carcinomas of thyroid
**Core Concept**
The expression of a specific oncogene is linked to the development of Medullary thyroid carcinoma (MTC), a type of thyroid cancer arising from the parafollicular cells (also known as C cells). This oncogene plays a crucial role in the pathogenesis of MTC, which accounts for approximately 3-10% of all thyroid cancers.
**Why the Correct Answer is Right**
The RET proto-oncogene is the primary culprit behind the development of MTC. Activation of the RET gene leads to the formation of a constitutively active tyrosine kinase receptor, resulting in uncontrolled cell proliferation and tumor formation. Mutations in the RET gene are inherited in an autosomal dominant pattern, increasing the risk of developing MTC. In sporadic cases, RET mutations are also found, often due to somatic mutations. The RET pathway is a key regulator of cell growth, differentiation, and survival, and its dysregulation leads to oncogenesis.
**Why Each Wrong Option is Incorrect**
* **Option A:** The BRAF V600E mutation is more commonly associated with Papillary thyroid carcinoma (PTC) rather than MTC.
* **Option B:** The RAS gene mutations are implicated in various cancers, including thyroid cancer, but are not specifically linked to MTC.
* **Option D:** The TP53 gene mutations are associated with a range of cancers, including thyroid cancer, but are not the primary oncogene responsible for MTC.
**Clinical Pearl / High-Yield Fact**
MTC is often associated with multiple endocrine neoplasia type 2 (MEN2) syndromes, which are characterized by the combination of MTC, pheochromocytoma, and hyperparathyroidism. RET mutations are the underlying cause of these syndromes, making genetic testing a crucial tool for diagnosis and screening.
**Correct Answer:** C. RET proto-oncogene.